


- (b) antigens and sequences derived from prostate cell membranes;
- (c) PSMA and sequences of PSMA;
- (d) PSA and sequences of PSA;
- (e) prostate mucins and sequences of prostate mucins.

In response to the above requirement for restriction, Applicants hereby elect the invention of Group III, claims 23-30, for prosecution in this application. Further, in response to the election of species requirement, Applicants elect the species of Group (a), *i.e.*, antigens and sequences derived from a prostate cell lysate. Attorneys for Applicants note that upon allowance of a generic claim, Applicants will be entitled to consideration of claims to additional species written in dependent form, upon an allowed generic claim. Claims 23-30 presently read upon the elected species.

Attorneys for Applicants respectfully point out that on December 1, 1998, an Information Disclosure Statement was submitted with Revised PTO 1449 Form listing References AA through DM. As indicated in the Information Disclosure Statement, references AA-DK can be found in the file of Applicants' prior Application Serial No. 08/509,254; and a copy of references DL and DM were submitted for the file of this application. It is requested that the Examiner review all the cited references and that they be made of record in this application. If the references cannot be located, the Examiner is requested to call the undersigned to submit a new copy of each. The undersigned can be reached at (212) 790-2296 or (800) 760-9090.

Date July 8, 1999

Respectfully submitted,


Geraldine F. Baldwin 31,232
(Reg. No.)
PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090